Dog study results

Extended-release bupivacaine has been studied in dog models as part of the development for human use. These studies were centered on the local and systemic safety and tolerability of the suspension in a dog model of inguinal hernia repair and reported similar macroscopic and microscopic findings in control and bupivacaine liposome injectable suspension-treated animals at day 15. There were no significant adverse effects on wound healing using bupivacaine liposome injectable suspension at doses higher than expected with clinical use in dogs.

This same group also investigated the effects of repeated doses of bupivacaine liposome injectable suspension in

dogs. Dogs were injected twice weekly for a total of eight injections with bupivacaine liposome injectable suspension (at doses higher than clinically recommended), bupivacaine HCl, or saline, administered into the subcutaneous tissue over the scapulae. There were no observed clinical signs consistent with CNS toxicity and no ECG abnormalities. In the bupivacaine liposome injectable suspension group, the only difference observed as compared to the other groups was macroscopic and microscopic indications of mild-to-moderate granulomatous inflammation. These observations were considered a normal response to the liposomes.

Clinical Support

Your convenient one-stop source for viewing, downloading and sharing important information.

Learn more >


Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

NOCITA is now available.

Other therapeutics from Aratana






ENTYCE® (capromorelin oral solution)
provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE® provides safe, effective appetite stimulation.


IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.